We help pharma teams build connected drug-delivery programmes for inhaled medicines: turning recorded inhaler use into adherence, technique and real-world evidence. Connected devices, co-developed with Plastiape, run on the Respiro platform behind patient support, clinical studies and market-access dossiers.
What happens between a patient and their inhaler is often hard to review, leaving important questions for three groups.
Adherence to inhaled medicines is famously low, and technique is often poor, so even the best molecule underperforms when doses are missed, mistimed or mis-taken.
They carry the downstream cost of poorly-controlled disease (exacerbations, emergency visits, admissions) and increasingly want real-world proof of value before they reimburse and keep a therapy on formulary.
They often have limited visibility of inhaler use at home. Recorded use and inhalation technique can add context to clinical assessment.
Connected inhalers turn the lights back on: everyday use becomes a record of dose timing and inhalation technique, building the real-world evidence a connected programme runs on.
Respiro gives patients practical support between visits, gives clinicians a clearer record of recorded treatment use, and gives pharma teams a consented evidence trail that connects adherence, inhalation technique and outcomes.
Reminders, recorded use history and, with a sensor, inhalation-technique information.
Bring recorded inhaler use, timing and technique into view for clinical assessment.
Connect real inhaler use to clinical and economic endpoints, supporting payer discussions with evidence beyond refills and claims.
In earlier Respiro studies, participant groups that could see their own doses and technique showed better asthma-control scores and lower downstream costs. Every figure here is tied to a named study.
Figures come from individual Respiro studies: a cluster RCT (n=68, ERS 2022), a real-world service evaluation (n=59, RDD 2026) and earlier pilots. They describe study populations, not a promise of individual results. Conference results are labelled as such. See the evidence →
Respiro turns recorded inhaler data into evidence you can build on: timing and inhalation technique, linked to clinical and economic outcomes.
Recorded inhaler use adds what claims and EHR data cannot: time-stamped evidence of timing and technique, tied to your therapy.
Connect recorded inhaler-use and technique data to endpoints so trial teams can see what participants recorded.
Show recorded inhaler-use timing and inhalation technique alongside your endpoints, beyond refill, claims and EHR records.
Use programme-defined evidence to support value-based conversations.
Connected respiratory care runs the length of your programme: early clinical development, launch in regulated markets, then commercial volume and value-based access.
Use connected-inhaler data in studies to link recorded use and technique to outcomes, with endpoint definitions agreed for the study.
Connected inhalers for trialsBring a connected programme into regulated markets with payer dossiers built on device-linked records of real-world use.
Manufacture connected devices at commercial volume through Plastiape's RS01 inhaler platform and run outcomes-based agreements as evidence compounds.
Device heritage refers to Plastiape's RS01 inhaler platform; marketed products built on the RS01 are independent third parties, not Amiko partnerships. Outcomes-based access describes a commercial model, not a promise of individual results.
Respiro-connected hardware records inhaler-use events and inhalation-technique data. Co-developed with our device manufacturing partner Plastiape, each route is engineered to scale.
Choose a fully integrated route such as RS01X, or use an add-on module for inhalers already selected, launched or familiar to patients, so a connected upgrade fits your device, timeline and routine.
Respiro is developed under a medical-device quality system, and the inhaler it connects is built by Plastiape on a platform pharma already manufactures at commercial scale.
Developed under an ISO 13485:2016 QMS on secure cloud infrastructure, with GDPR- and HIPAA-aligned deployments and documentation for EU MDR and US FDA pathways.
Plastiape manufactures the RS01 inhaler platform in ISO 7 (Class 10,000) clean rooms.
Plastiape's RS01 platform has a Certificate of Compliance with the Medical Device Regulation (EU) 2017/745 and a Type III DMF on file with the FDA: regulatory groundwork that can support programme submissions for the RS01 platform.
Manufacturing and RS01 regulatory references relate to Plastiape's inhaler platform.
Bring together an RS01X or add-on route, the Respiro platform and Plastiape input for the questions your programme needs to answer.